Neurogene's stock price collapsed by 34.8% in pre-market trading after announcing data from the Phase I/II Rett syndrome ...

National Institutes of Health (NIH) scientists and collaborators say they have discovered a new way in which RAS genes, ...

TG4050: Promising Phase I data to be presented at SITC 2024 providing clinical proof of principle in adjuvant head and neck cancer setting Financial visibility confirmed into Q4 2025 Strasbourg, ...

Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation, a leader in IT, network and AI technologies, announced 24.1 month ...

allowing for control of tumors in vivo without the need for exogenous or engineered cytokines – – Posters include demonstration of advances in gene editing and transgene design that enable greater ...

Compelling 24.1-month median follow-up data presented at SITC 2024 showed that all patients treated with TG4050 after completion of an adjuvant ...

SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, today announced data supporting SOT201, its next-generation PD-1-targeting immunocytokine. The company also reported ...

Transgene, ProBioGen join forces to advance individualized cancer vaccine development: Strasbourg, France Thursday, November 7, 2024, 11:00 Hrs [IST] Transgene, a biotech company ...

The gene therapy improved annualized bleed rates, though a handful of study participants resumed factor IX prophylaxis.

ProBioGen’s AGE1.CR.PIX been developed as a stable proliferating avian cell line that is highly permissive for different ...

A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science), Volume 16, Issue 20 on October 17, 2024, entitled, "Werner syndrome RECQ ...

French biotech Transgene today revealed it has entered into a license agreement with Germany-based contract development and ...